Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck To Ship Hepatitis C Drug Victrelis To Pharmacies Within A Week

Executive Summary

Merck will begin shipping Victrelis (boceprevir) to pharmacies within a week, the company announced following FDA approval of the hepatitis C drug after market-close on May 13 – a time-frame that roughly coincides with expected FDA action on Vertex's Incivek (telaprevir).
Advertisement

Related Content

Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle
Telaprevir Labeling Advantages Should Offset Higher Price In Hepatitis C Battle
FDA Must Decide How To Handle Subgroups In Labeling For Boceprevir, Telaprevir
FDA Must Decide How To Handle Subgroups In Labeling For Boceprevir, Telaprevir
A Guide To Response-Guided Therapy
Advisory Panel Backs Broad Boceprevir Label, But With Discussion Of Drug's Data Limitations
Dual FDA Advisory Committee Reviews Shaping Up To Be A Showdown For Dueling Merck And Vertex Hepatitis C Drugs

Topics

Advertisement
UsernamePublicRestriction

Register

PS053404

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel